<DOC>
	<DOCNO>NCT02364310</DOCNO>
	<brief_summary>Medico-economics assessment ( cost-effectiveness ) unilateral carotid barostimulation Barostim NeoTM compare usual care patient resistant hypertension ( multicenter randomize , PROBE trial ) , followed-up 12 month , lifetime-long modeling .</brief_summary>
	<brief_title>Economic Evaluation Baroreceptor STIMulation Treatment Resistant HyperTensioN</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Main inclusion Criteria : 1875 old men woman Resistant hypertension 4 medication incl . thiazide thiazidelike diuretic appropriate dos + spironolactone ( unless spironolactone intolerance ) Essential hypertension document ( bilan &lt; 2 year old ) eGFR ≥ 30 ml/min/1,73 m2 No carotid condition associate contraindication Barostim NeoTM use Main exclusion Criteria : Patients document secondary hypertension , besides Obstructive Sleep Apnea Symptomatic orthostatic hypotension Patient prior syncope myocardial infarction , unstable angina pectoris , cerebrovascular within 3 month inclusion Patient type 1 diabetes mellitus Patient permanent atrial fibrillation Patient brachial circumference ≥ 46cm Patient BMI &gt; 45kg/m2 Pregnancy , breastfeed planning pregnancy within 2 year NeoTM implantation anatomic contraindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>baroreceptor stimulation</keyword>
	<keyword>Hypertension resistant</keyword>
</DOC>